● The moral of Dr. Martens’ five profit warnings in three years is “never trust a private equity-backed company that comes to market with a pitch that years of easy expansion lie ahead”, says Nils Pratley in The Guardian.
UNLIMITED
AstraZeneca’s Headache In China
AstraZeneca’s third-quarter results eclipsed analysts’ forecasts, boosted by cancer and diabetes medicines, says Helena Smolak in The Wall Street Journal. However, both the good news and the announcement of another $2bn of investment have been oversh